305 related articles for article (PubMed ID: 12225393)
1. A prospective study of P-IMVP-16/CBDCA: a novel salvage chemotherapy for patients with aggressive non-Hodgkin's lymphoma who had previously received CHOP therapy as first-line chemotherapy.
Sawada M; Tsurumi H; Yamada T; Hara T; Fukuno K; Goto H; Shimizu M; Kasahara S; Yoshikawa T; Kanemura N; Oyama M; Takami T; Moriwaki H
Eur J Haematol; 2002 Jun; 68(6):354-61. PubMed ID: 12225393
[TBL] [Abstract][Full Text] [Related]
2. A salvage chemotherapy of R-P-IMVP16/CBDCA consisting of rituximab, methylprednisolone, ifosfamide, methotrexate, etoposide, and carboplatin for patients with diffuse large B cell lymphoma who had previously received R-CHOP therapy as first-line chemotherapy.
Matsumoto T; Hara T; Shibata Y; Nakamura N; Nakamura H; Ninomiya S; Kitagawa J; Kanemura N; Goto N; Kito Y; Kasahara S; Yamada T; Sawada M; Miyazaki T; Takami T; Takeuchi T; Moriwaki H; Tsurumi H
Hematol Oncol; 2017 Sep; 35(3):288-295. PubMed ID: 26999778
[TBL] [Abstract][Full Text] [Related]
3. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
4. Randomized phase II study of biweekly CHOP and dose-escalated CHOP with prophylactic use of lenograstim (glycosylated G-CSF) in aggressive non-Hodgkin's lymphoma: Japan Clinical Oncology Group Study 9505.
Itoh K; Ohtsu T; Fukuda H; Sasaki Y; Ogura M; Morishima Y; Chou T; Aikawa K; Uike N; Mizorogi F; Ohno T; Ikeda S; Sai T; Taniwaki M; Kawano F; Niimi M; Hotta T; Shimoyama M; Tobinai K;
Ann Oncol; 2002 Sep; 13(9):1347-55. PubMed ID: 12196359
[TBL] [Abstract][Full Text] [Related]
5. Failure of IMVP-16 as second-line treatment for relapsed or refractory high grade non-Hodgkin's lymphoma.
De Lord C; Newland AC; Linch DC; Vaughan Hudson B; Vaughan Hudson G
Hematol Oncol; 1992; 10(2):81-6. PubMed ID: 1592365
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of infusional chemotherapy with doxorubicin, vincristine and etoposide plus cyclophosphamide and prednisone (I-CHOPE) in resistant diffuse aggressive non-Hodgkin's lymphoma: CALGB 9255. Cancer and Leukemia Group B.
Lichtman SM; Niedzwiecki D; Barcos M; Carlisle TL; Cooper MR; Johnson JL; Peterson BA
Ann Oncol; 2000 Sep; 11(9):1141-6. PubMed ID: 11061609
[TBL] [Abstract][Full Text] [Related]
7. Feasibility of high-dose chemotherapy without stem cell support as a first-line treatment for non-Hodgkin's aggressive lymphoma: a pilot study.
Inoue R; Natazuka T; Shimoyama M; Tamekane A; Kajimoto Y; Iwata N; Matsuoka H; Chihara K; Matsui T
Leuk Lymphoma; 2000 Jan; 36(3-4):315-21. PubMed ID: 10674903
[TBL] [Abstract][Full Text] [Related]
8. Rituximab-CHOP-ESHAP vs CHOP-ESHAP-high-dose therapy vs conventional CHOP chemotherapy in high-intermediate and high-risk aggressive non-Hodgkin's lymphoma.
Intragumtornchai T; Bunworasate U; Nakorn TN; Rojnuckarin P
Leuk Lymphoma; 2006 Jul; 47(7):1306-14. PubMed ID: 16923561
[TBL] [Abstract][Full Text] [Related]
9. Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: identification of two age subgroups with differing hematologic toxicity.
Gómez H; Mas L; Casanova L; Pen DL; Santillana S; Valdivia S; Otero J; Rodriguez W; Carracedo C; Vallejos C
J Clin Oncol; 1998 Jul; 16(7):2352-8. PubMed ID: 9667250
[TBL] [Abstract][Full Text] [Related]
10. Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).
Wunderlich A; Kloess M; Reiser M; Rudolph C; Truemper L; Bittner S; Schmalenberg H; Schmits R; Pfreundschuh M; Loeffler M;
Ann Oncol; 2003 Jun; 14(6):881-93. PubMed ID: 12796026
[TBL] [Abstract][Full Text] [Related]
11. CEOP-IMVP-Dexa in the treatment of aggressive lymphomas: an Austrian multicenter trial.
Fridrik MA; Hausmaninger H; Linkesch W; Stöger M; Sill H; Neubauer M; Seewann HL; Klocker J; Haidinger R; Schiller L; Pont J; Raudaschl G; Falk M; Radaszkiewicz T
J Clin Oncol; 1996 Jan; 14(1):227-32. PubMed ID: 8558202
[TBL] [Abstract][Full Text] [Related]
12. Five-year follow-up of a prospective randomised multi-centre trial of weekly chemotherapy (CAPOMEt) versus cyclical chemotherapy (CHOP-Mtx) in the treatment of aggressive non-Hodgkin's lymphoma. Central Lymphoma Group.
Bailey NP; Stuart NS; Bessell EM; Child JA; Norfolk D; Fletcher J; Grieve RJ; Simmons AV; Barnard DL; Jack A; Farish J; Dunn J; Woodroffe CM; Stack C; Cullen MH
Ann Oncol; 1998 Jun; 9(6):633-8. PubMed ID: 9681077
[TBL] [Abstract][Full Text] [Related]
13. IMVP-16/Pd followed by high-dose chemotherapy and autologous stem cell transplantation as a salvage therapy for refractory or relapsed peripheral T-cell lymphomas.
Park BB; Kim WS; Lee J; Park KW; Kang JH; Lee SH; Park JO; Kim K; Jung CW; Park YS; Im YH; Kang WK; Ko YH; Lee MH; Park K
Leuk Lymphoma; 2005 Dec; 46(12):1743-8. PubMed ID: 16263576
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of delayed granulocyte colony-stimulating factor after full dose CHOP therapy in non-Hodgkin's lymphoma: a pilot study for a leukocyte count oriented regimen.
Sawada KI; Sato N; Kohno M; Hannda H; Yasukouchi T; Tanngo M; Hirayama A; Koike T
Leuk Lymphoma; 1995 Dec; 20(1-2):103-9. PubMed ID: 8750630
[TBL] [Abstract][Full Text] [Related]
15. Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma.
Arellano-Rodrigo E; López-Guillermo A; Bessell EM; Nomdedeu B; Montserrat E; Graus F
Eur J Haematol; 2003 Apr; 70(4):219-24. PubMed ID: 12656744
[TBL] [Abstract][Full Text] [Related]
16. Ifosfamide, etoposide, cytarabine, and methotrexate as salvage chemotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
Stamatoullas A; Fruchart C; Bastit D; Boulet D; Moncondult M; Piguet H; Tilly H
Cancer; 1996 Jun; 77(11):2302-7. PubMed ID: 8635099
[TBL] [Abstract][Full Text] [Related]
17. [Comparing CHOP, CHOP+HD-MTX,and BFM-90 regimens in the survival rate of children and adolescents with B cell non-Hodgkin's lymphoma].
Sun XF; Su YS; Liu DG; Jiang WQ; He YJ; Lin TY; Huang HQ; Zhang L; Xia ZJ; Li YH; Zhou ZM; Chen XQ; Xia Y; Zhen ZJ; Guan ZZ
Ai Zheng; 2004 Aug; 23(8):933-8. PubMed ID: 15301718
[TBL] [Abstract][Full Text] [Related]
18. European experience with ifosfamide in lymphomas.
von Kalle AK; Schaadt M; Diehl V
Semin Oncol; 1989 Feb; 16(1 Suppl 3):73-7. PubMed ID: 2468184
[TBL] [Abstract][Full Text] [Related]
19. High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy: a prospective randomized italian multicenter study.
Martelli M; Vignetti M; Zinzani PL; Gherlinzoni F; Meloni G; Fiacchini M; De Sanctis V; Papa G; Martelli MF; Calabresi F; Tura S; Mandelli F
J Clin Oncol; 1996 Feb; 14(2):534-42. PubMed ID: 8636768
[TBL] [Abstract][Full Text] [Related]
20. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]